Literature DB >> 17917886

A novel high-yield volume-reduction method for the cryopreservation of UC blood units.

G Koliakos1, D H Alamdari, N Tsagias, K Kouzi-Koliakos, E Michaloudi, V Karagiannis.   

Abstract

BACKGROUND: For the application of umbilical cord blood (UCB) units as hematopoietic grafts, a dose of 3.7 x 10(7) nucleated cells (NC)/kg body weight is required. NC can be lost during volume-reduction processing and during thawing. A novel modification of the double-processing protocol with the aim of minimizing NC loss is described and evaluated.
METHODS: One-hundred and fifty UCB were collected. The volume was reduced by a centrifugation step following double-processing in the presence of 2% HES 200/0.5. Pre- and post-processing cell counts and platelet parameters were measured with an automatic counter. The number of viable CD34+ hemopoietic stem cells was measured by flow cytometry. In 25 of the samples, colony-forming units (CFU) were also determined. The same samples were thawed 6 months after cryopreservation and re-evaluated.
RESULTS: The volume was reduced to 6 +/- 1.5 mL. The recovery of NC, MNC, CD34+ hemopoietic stem cells, RBC depletion and CFU following double-processing was 93.6 +/- 3.2%, 95.8 +/- 2.2%, 98.4 +/- 1.5%, 96.8 +/- 1.1% and 107.1 +/- 6.1% (for 25 samples), respectively. The post-thaw recoveries of NC, MNC, CD34+ hemopoietic stem cells and CFU (for 25 samples) were 78.6 +/- 5.4%, 90.8 +/- 4.4%, 96.4 +/- 2.5%, 89.1 +/- 4.1%, respectively. No post-thaw cell aggregation was observed. A significant (P<0.05) post-thaw loss of platelets and signs of platelet activation was observed. DISCUSSION: The protocol uses non-expensive equipment and clinically approved materials and results in samples that can be used in patients with a mean weight of 32.7 kg.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17917886     DOI: 10.1080/14653240701508445

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  4 in total

1.  Quality of long-term cryopreserved umbilical cord blood units for hematopoietic cell transplantation.

Authors:  Shohei Yamamoto; Hirokazu Ikeda; Daisuke Toyama; Mayumi Hayashi; Kousuke Akiyama; Manabu Suzuki; Yutaka Tanaka; Tsuneki Watanabe; Yoko Fujimoto; Ichirou Hosaki; Hirokazu Nishihira; Keiichi Isoyama
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

2.  Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art.

Authors:  Arianna Malgieri; Eugenia Kantzari; Maria Patrizia Patrizi; Stefano Gambardella
Journal:  Int J Clin Exp Med       Date:  2010-09-07

3.  Intramyocardial implantation of autologous bone marrow-derived stem cells combined with coronary artery bypass grafting in patients with ischemic cardiomyopathy: a pilot study.

Authors:  P Antonitsis; K Anastasiadis; G Koliakos; C Vaitsopoulou; K Kouzi-Koliakou; A Doumas; H Argiriadou; P Tossios
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

4.  Arsenic Primes Human Bone Marrow CD34+ Cells for Erythroid Differentiation.

Authors:  Yuanyuan Zhang; Shasha Wang; Chunyan Chen; Xiao Wu; Qunye Zhang; Fan Jiang
Journal:  Bioinorg Chem Appl       Date:  2015-06-11       Impact factor: 7.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.